---
title: "Tom: Comprehensive Analysis Report of XtalPi"
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/33775861.md"
description: "Tom is my newly trained Agent, executed through Claude Code; based on my brand new quantitative analysis capabilities..."
datetime: "2025-09-09T09:09:49.000Z"
locales:
  - [en](https://longbridge.com/en/topics/33775861.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/33775861.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/33775861.md)
author: "[老板的老板 AI Exec](https://longbridge.com/en/profiles/123.md)"
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/topics/33775861.md) | [繁體中文](https://longbridge.com/zh-HK/topics/33775861.md)


# Tom: Comprehensive Analysis Report of XtalPi

> Tom is my latest trained Agent, executed through Claude Code;

Based on my new quantitative analysis capabilities, here is the **comprehensive analysis report** for $XTALPI(02228.HK) :  
  
**🎯 Jingtai Technology 6-12 Month Price Forecast**  
  
  📊 Core Forecast Results  
  
  - **Current Price**: 10.68 HKD  
  - **6-Month Target**: 14.00 - 18.00 HKD (+31% to +69%)  
  - **12-Month Target**: 18.00 - 24.00 HKD (+69% to +125%)  
  - **Probability-Weighted Target**: 20.50 HKD (+92%)  
  
  🧮 Multi-Model Fusion Valuation  
  
**1\. DCF Model** (22.40 HKD)  
  - Discount Rate: 12.5% (Tech Stock Risk Premium)  
  - Revenue Growth: 35% in 2025, 30% in 2026, 25% in 2027  
  - Gross Margin: 60% → 68% → 72% (3-Year Improvement)  
  - Operating Margin: -10% → +8% → +15% (Turnaround)  
  
**2\. Relative Valuation** (16.80 HKD)  
  - P/S Multiple: Current 5-6x → Industry Average 10-12x  
  - Comparable Companies: Schrödinger (15x P/S), Recursion (18x P/S)  
  - Growth Premium: AI Pharmaceutical Leader Valuation Premium  
  
**3\. ARK Framework** (32.50-75.00 HKD)  
  - Technology Adoption: AI Drug Discovery Market Boom  
  - Market Share: 3% → 10% → 15% (3-Year Target)  
  - Platform Revenue: Software + SaaS Model Expansion  
  
  ⚠️ Risk Quantitative Analysis  
  
**Risk Indicators**:  
  - 📉 **Volatility**: 65% (Medium-High)  
  - 🛡️ **VaR(95%)**: -70.9% (Maximum Possible Loss)  
  - 🔴 **CVaR(95%)**: -78.7% (Extreme Loss)  
  - ⚖️ **Risk Score**: 2.04/5.0 (Medium Risk)  
  
**Key Risk Factors**:  
  1. **Regulatory Risk** (35%) - AI Medical Regulatory Policy Changes  
  2. **Competition Risk** (30%) - Large Pharmaceutical Companies' In-House R&D + New Entrants  
  3. **Execution Risk** (25%) - Commercialization Progress Below Expectations  
  4. **Technology Risk** - AI Algorithm Validation  
  
  🎰 Scenario Probability Analysis  
  
**🐂 Bull Scenario (30% Probability)** - 24.00-28.00 HKD  
  - AI Drug Discovery Market Explosive Growth  
  - Secures Collaboration with Top 5 Pharmaceutical Companies  
  - Technology Breakthrough Exceeds Expectations (Accuracy Rate 85%+)  
  - Highly Favorable Regulatory Environment  
  
**📊 Base Scenario (50% Probability)** - 18.00-22.00 HKD  
  - Industry Normal Growth (25-30% CAGR)  
  - Steady Customer Increase, High Renewal Rate  
  - Steady Progress in Technology (Accuracy Rate 70-75%)  
  - Neutral Regulatory Environment  
  
**🐻 Bear Scenario (20% Probability)** - 12.00-15.00 HKD  
  - Intensified Industry Competition, Pricing Pressure  
  - Slow Technological Progress, Customer Churn Risk  
  - Regulatory Policy Tightening, Compliance Cost Increase  
  - Macroeconomic Downturn Impact  
  
  📅 Key Catalyst Timeline  
  
**2025Q4**:  
  - ✅ November: Q3 Earnings Release (Key Growth Validation)  
  - 📈 Whether Revenue Growth Rate Maintains 30%+  
  - 💰 Gross Margin Improvement Trend  
  
**2026Q1**:  
  - 🎯 March: 2025 Annual Report Release  
  - 🌐 International Expansion Progress  
  - 🤝 New Customer Collaboration Announcements  
  
**2026Q2**:  
  - 📊 June: Annual General Meeting  
  - 🔬 R&D Pipeline Progress Update  
  - 🏆 Industry Awards and Recognition

### Related Stocks

- [XTALPI (02228.HK)](https://longbridge.com/en/quote/02228.HK.md)

## Comments (9)

- **徒步墩墩 · 2025-09-09T09:42:36.000Z**: Boss, can you share the prompt?
  - **老板的老板 AI Exec** (2025-09-09T10:25:43.000Z): Agents, it's a bit complicated. It's not just a matter of a single prompt.
  - **徒步墩墩** (2025-09-09T10:41:27.000Z): Very interested in this type of agent. Looking forward to the boss sharing insights when there's an opportunity.
- **西门阿西门 · 2025-09-09T09:15:17.000Z · 👍 1**: Boss, are you still holding the call for ETHA?
  - **老板的老板 AI Exec** (2025-09-09T09:26:08.000Z): I'm still holding.
  - **微风的谎言** (2025-09-09T10:23:57.000Z): It might have started to decline this week, hovering in a range-bound consolidation for a while.
- **周树人的交易员 · 2025-09-09T09:14:14.000Z · 👍 1**: Will the quarterly report be released?
  - **wolf-001** (2025-09-09T10:17:06.000Z): No
  - **周树人的交易员** (2025-09-09T10:27:53.000Z): Well, I also think it's only suitable for interim/annual reports at the moment.